How much revenue does Shanghai MicroPort Endovascular MedTech make?

Shanghai MicroPort Endovascular MedTech reported 1.21 billion CNY in revenue for fiscal year 2024, up 1.6% from 1.19 billion CNY in fiscal year 2023. In Q2 2025 revenue was 382.24 million CNY.

Where does Shanghai MicroPort Endovascular MedTech make most of its revenue?

China: 81% of revenue by region in fiscal year 2025, followed by Overseas (19%).

What companies are similar to Shanghai MicroPort Endovascular MedTech?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Micro-Tech (Nanjing) Co.,Ltd (688029.SS), Autek China Inc. (300595.SZ), Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS), Mingyue Optical Lens Co.,Ltd. (301101.SZ).

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) Stock

About Shanghai MicroPort Endovascular MedTech Co., Ltd.

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system...

At a glance

Shanghai MicroPort Endovascular MedTech reported revenue of 1.21 billion CNY for fiscal year 2024, up 1.6% from fiscal year 2023, and net income of 502.10 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 382.24 million CNY, down 10.9% from a year before. China was its largest region in fiscal year 2025, with 81% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.